Byondis
Annemarie van Lith is an experienced professional in the biopharmaceutical industry, currently serving as Senior Team Leader USP & DSP at Byondis since January 2020. With a robust background in cell culture, disposable technology, and GMP, Annemarie has expertise in small and large-scale mAb production, tech transfer, and manufacturing readiness for clinical phases. Prior to Byondis, Annemarie held roles at Synthon, including Teamleader USP and USP/Cell Line Development Researcher, where skills in project management and process validation were honed. Earlier experiences include internships in molecular biology and various roles at Albert Heijn. Annemarie holds a Bachelor's degree in biochemistry from HAN University of Applied Sciences and further education from Rijn IJssel College.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.